Yeon Hee Park, MD

Yeon Hee Park, MD, discusses the unmet needs in among premenopausal patients with metastatic breast cancer.

Yeon Hee Park, MD, discusses the data supporting the FDA’s accelerated approval of fam-trastuzumab deruxtecan-nxki for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received ≥2 prior anti–HER2-based regimens in the metastatic setting.